Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revitensin
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
Revitensin is an over-the-counter product developed and marketed by PharmaSGP for the supportive treatment of various forms of hair loss, including androgenetic alopecia, alopecia areata, and diffuse hair loss. In Germany, Revitensin is approved as a homeopathic medicine formulated as oral drops, featuring a multi-target complex of five active dilutions: Acidum hydrofluoricum (D12), Graphites (D8), Pel talpae (D8), Selenium (D12), and Thallium metallicum (D12). In other European markets such as Italy, Revitensin is distributed as a dietary supplement containing the CX-9 active complex, which includes Serenoa repens, L-cysteine, millet extract, biotin, and various minerals. Both formulations are designed to combat hair loss and promote hair health from within.
- Brand names
- Revitensin
Beyond the preview
Go deeper on Revitensin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revitensin.